GSK shareholders to vote on Novartis megadeal in December

Glaxo shareholders will soon have the chance to weigh in on an asset swap between GlaxoSmithKline ($GSK) and Novartis ($NVS) worth more than $20 billion. The British pharma giant has asked its investors to vote at a Dec. 18 meeting on the proposed deal, which will send GSK's oncology drugs to Switzerland and most of Novartis' flu business to Glaxo, as well as establish a consumer healthcare JV. "This is the most significant transaction for the company since the creation of GlaxoSmithKline in 2000," GSK chairman Christopher Gent wrote in a shareholder letter seen by ReutersNews | More

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.